Is Now the Time to Buy 3 of the S&P 500's Worst-Performing Stocks of 2024?

Group 1: Market Overview - The S&P 500 has reached record levels in 2024, with many stocks providing excellent returns for investors, while some companies have struggled significantly [1] - Several companies within the S&P 500 have seen sharp declines in their stock prices due to difficulties in growth and lack of near-term catalysts [2] Group 2: Walgreens Boots Alliance - Walgreens Boots Alliance has experienced a 65% decline in stock value this year, attributed to an uncertain future, losses in three of the last four quarters, and a dividend cut [3] - The company faces challenges from competitors like Amazon, which is expanding same-day delivery for prescriptions, potentially impacting Walgreens' already thin margins [4] - The new CEO must demonstrate a viable path to profitability and long-term growth for the stock to recover, but current risks make it a poor investment choice [5] Group 3: Moderna - Moderna's stock has dropped 57%, erasing pandemic gains, with a significant revenue decline of 64% last year to $6.8 billion due to reduced government purchases of COVID vaccines [6][7] - The company is diversifying its portfolio but lacks compelling new products to attract investors, relying heavily on COVID sales which have not been sustainable [7] - Potential recovery hinges on the approval of a personalized cancer vaccine in phase 3 trials, but historical high failure rates in cancer treatments pose significant risks [8][9] Group 4: Intel - Intel's stock has decreased by 52% as investors recognize ongoing challenges, including declining revenue and unprofitable ventures in its foundry business [10] - The foundry segment reported a loss of $5.8 billion in the last quarter, worsening from a $1.4 billion loss in the same period the previous year, with an 8% decline in sales [11] - For recovery, Intel must prove that its foundry business can become profitable and that there is substantial demand, but investor confidence remains low [12]